



Contact: Ronald Trahan, APR, Ronald Trahan Associates Inc., 508-359-4005, x108

## Elemé Medical announces \$18 million “Series C” financing

MERRIMACK, N.H., July 16, 2008 — **Elemé Medical Inc.**, a private venture-backed **aesthetics** company building a franchise in the **body shaping** market with an initial focus on **treatment of cellulite**, announced today that it has raised **\$18 million** in a “**Series C**” financing led by **L Capital Partners** ([www.lcapitalpartners.com](http://www.lcapitalpartners.com)). The C round also included new investor **Hambrecht & Quist Capital Management** ([www.hqcm.com](http://www.hqcm.com)), as well as returning investors **Three Arch Partners** ([www.threearchpartners.com](http://www.threearchpartners.com)) and **EDF Ventures** ([www.edfvc.com](http://www.edfvc.com)). The funds will be used to commercialize the Company’s FDA-cleared **SmoothShapes® System** and also to develop the Company’s pipeline of body shaping technologies. **Ting Pau Oei**, a partner at L Capital Partners, and **Daniel R. Omstead, Ph.D.**, President and CEO of Hambrecht & Quist Capital Management, will join the board of directors of Elemé Medical.

The SmoothShapes® System uses a proprietary technology called **Photomology®** to treat the underlying causes of cellulite. Thermal and non-destructive, Photomology’s unique mechanism of action combines dynamic laser *and* light energy *with* mechanical massage and vacuum to specifically affect the underlying tissue responsible for the visible manifestations of cellulite. Results include improved appearance of cellulite with **tighter, smoother skin that patients can see and feel**.

“The fact that we have raised a significant round of financing from sophisticated investors in a *down* market bears strong testimony to the validity of our approach to treating cellulite,” said **Nancy M. Briefs**, President and CEO. “We have said all along that our claims about SmoothShapes are based *exclusively* on results obtained in rigorous, independent and ongoing clinical studies of the System. Indeed, the due diligence conducted by our new investors and their ensuing investment in Elemé Medical further substantiates our technology’s robust scientific foundation.”

“We are intrigued by the immense size of the potential market for the SmoothShapes device,” explained lead investor L Capital Partners’ **Ting Pau Oei**, who spent 22 years prior to joining L Capital Partners at Johnson & Johnson, the last 12 at JJDC, Johnson & Johnson’s venture capital arm. “Equally important, Elemé Medical’s pipeline of other patented technologies is considerable, with 35 issued patents in the portfolio, thereby providing a very substantial barrier to entry in the body shaping sector.”

### About Elemé Medical

Elemé Medical Inc., headquartered in Merrimack, N.H., is dedicated to providing market-leading technology in all areas of body contouring. Its **SmoothShapes® System**, a medical device with **FDA clearance** to market, launched in spring 2008. For more information, visit [www.elememedical.com](http://www.elememedical.com).

#####